Clifford Swan Investment Counsel LLC Sells 12,433 Shares of Novartis AG $NVS

Clifford Swan Investment Counsel LLC trimmed its stake in shares of Novartis AG (NYSE:NVS) by 17.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 60,118 shares of the company’s stock after selling 12,433 shares during the period. Clifford Swan Investment Counsel LLC’s holdings in Novartis were worth $9,422,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in shares of Novartis by 76.5% in the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock worth $599,000 after buying an additional 2,666 shares during the last quarter. AQR Capital Management LLC increased its position in Novartis by 102.8% during the first quarter. AQR Capital Management LLC now owns 22,573 shares of the company’s stock valued at $2,516,000 after acquiring an additional 11,444 shares during the last quarter. Empowered Funds LLC bought a new position in Novartis in the first quarter valued at about $1,764,000. Sivia Capital Partners LLC lifted its holdings in Novartis by 48.0% in the second quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock valued at $963,000 after acquiring an additional 2,581 shares during the period. Finally, Schnieders Capital Management LLC. purchased a new position in Novartis in the second quarter worth about $202,000. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Wall Street Analysts Forecast Growth

NVS has been the subject of several research reports. Citigroup reaffirmed a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Weiss Ratings restated a “buy (b)” rating on shares of Novartis in a research report on Friday, July 24th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $141.20.

Novartis Price Performance

NYSE NVS opened at $152.22 on Tuesday. The business’s fifty day moving average is $155.14 and its 200 day moving average is $153.72. Novartis AG has a fifty-two week low of $121.57 and a fifty-two week high of $170.46. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86. The company has a market capitalization of $290.46 billion, a PE ratio of 22.96, a price-to-earnings-growth ratio of 2.64 and a beta of 0.45.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.The business had revenue of $14.95 billion during the quarter. Sell-side analysts predict that Novartis AG will post 8.84 earnings per share for the current year.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.